Secondary amenorrhea reveals a polyglandular autoimmune syndrome of type II

Collée Julie¹, Potorac Iulia², Nisolle Michelle¹, Beckers Albert²

Departements of gynaecology ¹ and endocrinology ², CHU de Liège, Liège Belgium.

Introduction:

Auto-immune polyglandular syndrome type 2 (APS-II) is an autoimmune condition which combines Addison's disease (primary adrenal insufficiency) with another autoimmune pathology like thyroiditis, diabete mellitus, primary hypogonadism, vitiligo, Biermer anemia, etc. Patients can develop those pathologies concurrently or many years after the first manifestation. Prevalence of APS-II is 1 or 2 cases/100.000/year and the sex ratio is 3 women for 1 man. Genetic transmission is polygenic and multifactorial, suggesting an impact from the environment. Polymorphism of genes HLA, CTLA-4 and PTPN22 could explain this complex transmission. Different polyglandular autoimmune syndromes exist, each one distinguished by the genetics and the organs it affects.

Case:

We report a case of a 37-year's old woman addressed at our Endocrinology department for a secondary amenorrhea. After stopping her contraception, menstruations did not come back for six months and she lost nine kilograms in nearly six months. Nauseas, loss of appetite and flushes were present. Hashimoto thyroiditis has been diagnosed six years ago and therefore the thyroid function was substituted by 75 micrograms thyroxine. Explorations consisted in hormonal blood test, karyotype, ACTH test and renin activity measurement. High levels of gonadotrophins and ACTH in combination with low levels of estrogens, cortisol, aldosterone and DHEA suggested a deficit of hormonal secretion. Anti-adrenal and anti-ovary antibodies were detected in the blood test. Karyotype was 46XX. The ACTH test revealed an incapacity for the adrenal glands to produce and deliver cortisol (glucocorticoids). The aldosterone/renin activity measurements showed a deficit in mineralocorticoid secretion. The diagnosis of autoimmune oophoritis and Addison's disease was considered. Glucocorticoid (hydrocortisone) and mineralocorticoid (9-α-fluorohydrocortisone) substitution treatment was initiated.

Discussion:

One percent of women beneath 40 years suffer from autoimmune oophoritis which could also be one of the manifestations of APS. Therefore this diagnosis should be kept in mind when exploring secondary amenorrhea in young females. Antibodies attack steroid synthesis enzymes as 21-hydroxylase, 17-alpha hydroxylase and P450scc cytochrome. Autoimmune oophoritis results in a specific aggression of thecal cells causing a lack of estrogens but sparing preantral follicules. Preantral and antral follicules produce antimullerian hormone (AMH), which is a biological marker of the reserve of follicules. The AMH level remains high in autoimmune oophoritis. According to those findings, the pool of follicules seems to be preserved in autoimmune ovarian insufficiency cases. Immunomodulators could reduce the inflammation and protect the ovarian function. Glucocorticoid administration may partly restore the ovarian activity and two months after the intake, ovulation can occur but menstrual cycles remain fluctuant.

Bibliography

- 1) J-L. Wémeau, E. Proust-Lemoine, A. Ryndak, L. Vanhove. Thyroid autoimmunity and polyglandular endocrine syndromes. Hormones. 2013, 12(1):39-45
- 2) A. Falorni, A. Brozzetti, M-C. Aglietti, R. Esposito, V. Minarelli, S. Morelli, E. Sbroma Tomaro and S. Marzotti, Progressive decline of residual follicle pool after clinical diagnosis of autoimmune ovarian insufficiency. Clinical Endocrinology. 2012. 77: 453–458
- 3) VK. Bakalov, JN. Anasti, KA. Calis, VH. Vanderhoof, A. Premkumar, S. Chen, J. Furmaniak, B. Rees Smith, MJ. Merino, LM. Nelson. Autoimmune oophoritis as a mechanism of follicular dysfunction in women with 46,XX spontaneous premature ovarian failure. Fertility and Sterility. 2005, 84 (4): 958-965.
- 4) GJ. Kahaly. Polyglandular auto-immune syndrome type II. Presse médicale, 2012, 41(12): 663-670.
- 5) M. Cutulo. Autoimmune polyendocrine syndromes. Autoimmunity reviews, 2014. 13: 85-89.
- 6) CA. Silva, LYS. Yamakami, NE. Aikawa, DB. Araujo, JF. Carvalho, E. Bonfa. Autoimmune primary ovarian insufficiency. Autoimmunity reviews. 2014 (13): 427-430
- 7) A. Bain, M. Stewart, P. Mwamure, K. Nirmalaraj. Addison's disease in a patient with hypothyroidism: autoimmune polyglandular syndrome type 2. BMJ Case report, 2015: 1-3.
- 8) D. Schubert, C. Bode, R. Kenefeck, B. Grimbacher et al. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nature medicine. 2014. 20 (12): 1410-1416.
- 9) JL. Wémeau, Polyendocrinopathies auto-immunes de type 2, Revue du Praticien, 2014. 64: 838-839.
- 10) R. Zbadi, S. Derrou, H. Ouleghzal, S. Safi. Polyendocrinopathie de type II: une association intrinquée. CHU Hassan II.